Medispan Recognized for Technological Prowess and Innovation in Joint Development of Immune Booster

Medispan, a domestic bio venture, has been recognized for its technological prowess and innovation through the joint development of an immune booster with the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

The company was selected for the ‘TIPS Startup Commercialization and Overseas Marketing Support Project’ hosted by the Ministry of SMEs and Startups, in recognition of its achievements. The TIPS program is a representative startup fostering program that supports private-led technology startups.

With this selection, Medispan will receive up to 200 million won in additional funding for startup commercialization and overseas marketing. This funding will be used for technology development for efficacy evaluation and mechanism research on aging and various geriatric diseases.

A company official stated, “This selection has once again proven Medispan’s active international joint research and development achievements.” Medispan was the first overseas company to be invited to a seminar hosted by NIAID, introducing its technology to the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), the Bill Gates Foundation, and vaccine development officials in the United States.

Medispan has signed a material transfer agreement (MTA) with Duke University, Stanford University, and the University of California, in the U.S. to develop large-scale immune enhancers that can improve the efficacy of infectious disease vaccines, anticancer drugs, allergies, etc., led by the NIAID. The company has also completed drug delivery for large-scale evaluation of the substances.

Kyung-ah Cho, CEO of Medispan, stated, “We are jointly developing MSP-102 with our partners in the United States and preparing to enter the global market through NIAID’s clinical support program.” Cho continued, “MSP-102 is a next-generation nasal immune enhancer targeting aging and infectious diseases, and we are currently conducting development and mechanism elucidation research with Stanford University Professor Bali Plendran.”

CEO Cho expressed his aspirations, saying, “The government is currently preparing various support projects for aging-related research and securing global competitiveness. We will proceed with the development of MSP-102 in cooperation with domestic and foreign partners and successfully enter the global market through NIAID’s clinical support program.”

Key Points:

• Medispan selected for the ‘TIPS Startup Commercialization and Overseas Marketing Support Project’ hosted by the Ministry of SMEs and Startups.
• Company to receive up to 200 million won in additional funding for startup commercialization and overseas marketing.
• Medispan jointly developing MSP-102 with partners in the United States and preparing to enter the global market through NIAID’s clinical support program.